Difference between revisions of "Hodgkin lymphoma, nodular lymphocyte-predominant"
m |
m |
||
Line 3: | Line 3: | ||
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
− | {{TOC limit|limit= | + | {{TOC limit|limit=3}} |
− | =ABVD= | + | =Untreated= |
+ | |||
+ | ==ABVD== | ||
ABVD: '''<u>A</u>'''driamycin, '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | ABVD: '''<u>A</u>'''driamycin, '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | ||
− | ==Regimen== | + | ===Regimen=== |
− | *[[Doxorubicin (Adriamycin)]] 25 mg/m2 IV days 1 & 15 | + | *[[Doxorubicin (Adriamycin)]] 25 mg/m2 IV once on days 1 & 15 |
− | *[[Bleomycin (Blenoxane)]] 10 units/m2 IV days 1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose) | + | *[[Bleomycin (Blenoxane)]] 10 units/m2 IV once on days 1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose) |
− | *[[Vinblastine (Velban)]] 6 mg/m2 IV days 1 & 15 | + | *[[Vinblastine (Velban)]] 6 mg/m2 IV once on days 1 & 15 |
− | *[[Dacarbazine (DTIC)]] 375 mg/m2 IV days 1 & 15 | + | *[[Dacarbazine (DTIC)]] 375 mg/m2 IV once on days 1 & 15 |
*+/- [[Rituximab (Rituxan)]]; schedule & number of cycles is not well-established. One potential option is 375 mg/m2 IV weekly x 4 weeks on cycle 1 (see [[#Single_agent_Rituximab_.28Rituxan.29|single agent rituximab]]). Use in subsequent cycles is not well-documented. | *+/- [[Rituximab (Rituxan)]]; schedule & number of cycles is not well-established. One potential option is 375 mg/m2 IV weekly x 4 weeks on cycle 1 (see [[#Single_agent_Rituximab_.28Rituxan.29|single agent rituximab]]). Use in subsequent cycles is not well-documented. | ||
− | '''28-day cycles x 2 | + | '''28-day cycles x 2 to 6 cycles''' based on stage, response, and whether radiation therapy is used. |
− | ==References== | + | ===References=== |
# Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011 Oct 27;118(17):4585-90. [http://bloodjournal.hematologylibrary.org/content/118/17/4585.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21873543 PubMed] | # Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011 Oct 27;118(17):4585-90. [http://bloodjournal.hematologylibrary.org/content/118/17/4585.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21873543 PubMed] | ||
− | =CHOP= | + | ==CHOP== |
CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | ||
− | ==Regimen== | + | ===Regimen=== |
− | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV day 1 | + | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV once on day 1 |
− | *[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV day 1 | + | *[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV once on day 1 |
− | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV day 1 | + | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1 |
− | *[[Prednisone (Sterapred)]] 100 mg PO days 1 | + | *[[Prednisone (Sterapred)]] 100 mg PO once daily on days 1 to 5 |
− | '''21-day cycles x 6 | + | '''21-day cycles x 6 to 8 cycles''' (number of cycles for CHOP in LPHL is not well-established) |
− | ==References== | + | ===References=== |
# Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. [http://jco.ascopubs.org/content/23/18/4117.full link to original article] '''contains protocol'''--this was for diffuse large B-cell lymphomas; no primary reference available for use of CHOP in LPHL [http://www.ncbi.nlm.nih.gov/pubmed/15867204 PubMed] | # Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. [http://jco.ascopubs.org/content/23/18/4117.full link to original article] '''contains protocol'''--this was for diffuse large B-cell lymphomas; no primary reference available for use of CHOP in LPHL [http://www.ncbi.nlm.nih.gov/pubmed/15867204 PubMed] | ||
− | =R-CHOP= | + | ==R-CHOP== |
R-CHOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | R-CHOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | ||
− | ==Regimen== | + | ===Regimen=== |
− | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV day 1 | + | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV once on day 1 |
− | *[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV day 1 | + | *[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV once on day 1 |
− | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV day 1 | + | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1 |
− | *[[Prednisone (Sterapred)]] 100 mg PO days 1 | + | *[[Prednisone (Sterapred)]] 100 mg PO once daily on days 1 to 5 |
− | *[[Rituximab (Rituxan)]] 375 mg/m2 IV day 1 | + | *[[Rituximab (Rituxan)]] 375 mg/m2 IV once on day 1 |
− | '''21-day cycles x 6 | + | '''21-day cycles x 6 to 8 cycles''' (number of cycles for R-CHOP in LPHL is not well-established) |
− | ==References== | + | ===References=== |
See [[#CHOP|references for CHOP]] | See [[#CHOP|references for CHOP]] | ||
− | =CVP= | + | ==CVP== |
CVP: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone | CVP: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone | ||
− | ==Regimen== | + | ===Regimen=== |
− | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV day 1 | + | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV once on day 1 |
− | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV day 1 | + | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1 |
− | *[[Prednisone (Sterapred)]] 40 mg/m2 PO days 1 | + | *[[Prednisone (Sterapred)]] 40 mg/m2 PO once daily on days 1 to 5 |
'''21-day cycles x up to 8 cycles''' (number of cycles for CVP in LPHL is not well-established) | '''21-day cycles x up to 8 cycles''' (number of cycles for CVP in LPHL is not well-established) | ||
− | ==References== | + | ===References=== |
# Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105(4):1417-23. [http://bloodjournal.hematologylibrary.org/content/105/4/1417.full link to original article] '''contains protocol'''--this was for follicular lymphoma; no primary reference available for use of CVP in LPHL [http://www.ncbi.nlm.nih.gov/pubmed/15494430 PubMed] | # Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105(4):1417-23. [http://bloodjournal.hematologylibrary.org/content/105/4/1417.full link to original article] '''contains protocol'''--this was for follicular lymphoma; no primary reference available for use of CVP in LPHL [http://www.ncbi.nlm.nih.gov/pubmed/15494430 PubMed] | ||
− | =R-CVP= | + | ==R-CVP== |
R-CVP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone | R-CVP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone | ||
− | ==Regimen== | + | ===Regimen=== |
− | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV day 1 | + | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV once on day 1 |
− | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV day 1 | + | *[[Vincristine (Oncovin)]] 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1 |
− | *[[Prednisone (Sterapred)]] 40 mg/m2 PO days 1 | + | *[[Prednisone (Sterapred)]] 40 mg/m2 PO once daily on days 1 to 5 |
− | *[[Rituximab (Rituxan)]] 375 mg/m2 IV day 1 | + | *[[Rituximab (Rituxan)]] 375 mg/m2 IV once on day 1 |
'''21-day cycles x up to 8 cycles''' (number of cycles for R-CVP in LPHL is not well-established) | '''21-day cycles x up to 8 cycles''' (number of cycles for R-CVP in LPHL is not well-established) | ||
− | ==References== | + | ===References=== |
See [[#CVP|references for CVP]] | See [[#CVP|references for CVP]] | ||
− | =EPOCH= | + | ==EPOCH== |
EPOCH: '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin | EPOCH: '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin | ||
− | ==Regimen #1, Wilson, et al. 1993 - original EPOCH protocol== | + | ===Regimen #1, Wilson, et al. 1993 - original EPOCH protocol=== |
− | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 | + | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4 |
− | *[[Prednisone (Sterapred)]] 60 mg/m2/day PO on days 1 | + | *[[Prednisone (Sterapred)]] 60 mg/m2/day PO on days 1 to 5 (regimen originally was days 1 to 6, but now is just days 1 to 5) |
− | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (sometimes capped at maximum total dose of 2mg per cycle) IV continuous infusion on days 1 | + | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (sometimes capped at maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4 |
− | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 | + | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4 |
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 (regimen originally was day 6, but now is day 5) | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 (regimen originally was day 6, but now is day 5) | ||
*PCP prophylaxis (choose one) | *PCP prophylaxis (choose one) | ||
Line 85: | Line 87: | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | *[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | ||
− | '''21-day cycles x 6 | + | '''21-day cycles x 6 to 8 cycles''' |
− | ==Regimen #2, Wilson, et al. 2002 - dose-adjusted EPOCH== | + | ===Regimen #2, Wilson, et al. 2002 - dose-adjusted EPOCH=== |
− | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 | + | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4 |
− | *[[Prednisone (Sterapred)]] 60 mg/m2 PO BID on days 1 | + | *[[Prednisone (Sterapred)]] 60 mg/m2 PO BID on days 1 to 5 |
− | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (not capped in the paper, but sometimes capped at a maximum total dose of 2mg per cycle) IV continuous infusion on days 1 | + | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (not capped in the paper, but sometimes capped at a maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4 |
− | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 | + | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4 |
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 | ||
Line 100: | Line 102: | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | *[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | ||
− | '''21-day cycles x 6 | + | '''21-day cycles x 6 to 8 cycles''' |
Dose-adjustments for EPOCH protocol: | Dose-adjustments for EPOCH protocol: | ||
Line 121: | Line 123: | ||
*If ANC nadir is >500 and patient had previously been dose-reduced, increase cyclophosphamide dose by 187 mg/m2 | *If ANC nadir is >500 and patient had previously been dose-reduced, increase cyclophosphamide dose by 187 mg/m2 | ||
− | ==References== | + | ===References=== |
# Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993 Aug;11(8):1573-82 [http://jco.ascopubs.org/content/11/8/1573.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7687667 PubMed] | # Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993 Aug;11(8):1573-82 [http://jco.ascopubs.org/content/11/8/1573.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7687667 PubMed] | ||
# Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685-93. [http://bloodjournal.hematologylibrary.org/content/99/8/2685.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11929754 PubMed] content property of [http://hemonc.org HemOnc.org] | # Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685-93. [http://bloodjournal.hematologylibrary.org/content/99/8/2685.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11929754 PubMed] content property of [http://hemonc.org HemOnc.org] | ||
# Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008 Jun 1;26(16):2717-24. [http://jco.ascopubs.org/content/26/16/2717.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18378569 PubMed] | # Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008 Jun 1;26(16):2717-24. [http://jco.ascopubs.org/content/26/16/2717.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18378569 PubMed] | ||
− | =R-EPOCH= | + | ==R-EPOCH== |
R-EPOCH: '''<u>R</u>'''ituximab, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin | R-EPOCH: '''<u>R</u>'''ituximab, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin | ||
− | ==Regimen #1, Wilson, et al. 1993 - original EPOCH protocol (which did not include rituximab)== | + | ===Regimen #1, Wilson, et al. 1993 - original EPOCH protocol (which did not include rituximab)=== |
*[[Rituximab (Rituxan)]] 375 mg/m2 IV once per cycle (usually given as outpatient due to reimbursement issues) | *[[Rituximab (Rituxan)]] 375 mg/m2 IV once per cycle (usually given as outpatient due to reimbursement issues) | ||
− | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 | + | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4 |
− | *[[Prednisone (Sterapred)]] 60 mg/m2/day PO on days 1 | + | *[[Prednisone (Sterapred)]] 60 mg/m2/day PO on days 1 to 5 (regimen originally was days 1 to 6, but now is just days 1 to 5) |
− | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (sometimes capped at maximum total dose of 2mg per cycle) IV continuous infusion on days 1 | + | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (sometimes capped at maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4 |
− | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 | + | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4 |
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 (regimen originally was day 6, but now is day 5) | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 (regimen originally was day 6, but now is day 5) | ||
*PCP prophylaxis (choose one) | *PCP prophylaxis (choose one) | ||
Line 141: | Line 143: | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | *[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | ||
− | '''21-day cycles x 6 | + | '''21-day cycles x 6 to 8 cycles''' |
− | ==Regimen #2, Wilson, et al. 2002 - dose-adjusted EPOCH== | + | ===Regimen #2, Wilson, et al. 2002 - dose-adjusted EPOCH=== |
*[[Rituximab (Rituxan)]] 375 mg/m2 IV once per cycle (usually given as outpatient due to reimbursement issues) | *[[Rituximab (Rituxan)]] 375 mg/m2 IV once per cycle (usually given as outpatient due to reimbursement issues) | ||
− | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 | + | *[[Etoposide (Vepesid)]] 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4 |
− | *[[Prednisone (Sterapred)]] 60 mg/m2 PO BID on days 1 | + | *[[Prednisone (Sterapred)]] 60 mg/m2 PO BID on days 1 to 5 |
− | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (not capped in the paper, but sometimes capped at a maximum total dose of 2mg per cycle) IV continuous infusion on days 1 | + | *[[Vincristine (Oncovin)]] 0.4 mg/m2/day (1.6 mg/m2 total) (not capped in the paper, but sometimes capped at a maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4 |
− | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 | + | *[[Doxorubicin (Adriamycin)]] 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4 |
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV over 15 minutes on day 5 | ||
Line 157: | Line 159: | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | *[[Filgrastim (Neupogen)]] 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir | ||
− | '''21-day cycles x 6 | + | '''21-day cycles x 6 to 8 cycles''' |
− | ==Dose-adjusted R-EPOCH protocol== | + | ===Dose-adjusted R-EPOCH protocol=== |
*Start cycle 1 as described above | *Start cycle 1 as described above | ||
*Obtain twice per week CBCs for nadir measurements | *Obtain twice per week CBCs for nadir measurements | ||
Line 169: | Line 171: | ||
*Can start new cycle Q21days if ANC >1,000 and platelets >100. If counts are below those levels, check daily CBC and continue growth factor support until counts are adequate and next cycle can start. | *Can start new cycle Q21days if ANC >1,000 and platelets >100. If counts are below those levels, check daily CBC and continue growth factor support until counts are adequate and next cycle can start. | ||
− | ==Historic dose adjustments for hematologic toxicity== | + | ===Historic dose adjustments for hematologic toxicity=== |
These adjustments were in the original paper for standard EPOCH, which are much less relevant due to growth factor support. | These adjustments were in the original paper for standard EPOCH, which are much less relevant due to growth factor support. | ||
<br>If ANC on day 1 is: | <br>If ANC on day 1 is: | ||
Line 178: | Line 180: | ||
*If ANC nadir is >500 and patient had previously been dose-reduced, increase cyclophosphamide dose by 187 mg/m2 | *If ANC nadir is >500 and patient had previously been dose-reduced, increase cyclophosphamide dose by 187 mg/m2 | ||
− | ==References== | + | ===References=== |
See [[#EPOCH|references for EPOCH]] | See [[#EPOCH|references for EPOCH]] | ||
− | =Single agent Rituximab (Rituxan)= | + | ==Single agent Rituximab (Rituxan)== |
− | ==Regimen== | + | ===Regimen=== |
*[[Rituximab (Rituxan)]] 375 mg/m2 IV weekly x 4 weeks | *[[Rituximab (Rituxan)]] 375 mg/m2 IV weekly x 4 weeks | ||
'''One course of 4 week therapy''' | '''One course of 4 week therapy''' | ||
− | ==Supportive medications== | + | ===Supportive medications=== |
*Acetaminophen 650 mg PO 30 minutes prior to each dose of rituximab | *Acetaminophen 650 mg PO 30 minutes prior to each dose of rituximab | ||
*Diphenhydramine (Benadryl) 25 mg PO 30 minutes prior to each dose of rituximab | *Diphenhydramine (Benadryl) 25 mg PO 30 minutes prior to each dose of rituximab | ||
− | ==References== | + | ===References=== |
# Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Jun 1;101(11):4285-9. [http://bloodjournal.hematologylibrary.org/content/101/11/4285.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12586628 PubMed] | # Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Jun 1;101(11):4285-9. [http://bloodjournal.hematologylibrary.org/content/101/11/4285.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12586628 PubMed] | ||
# Ibom VK, Prosnitz RG, Gong JZ, Moore JO, DeCastro CM, Prosnitz LR, Rizzieri DA, Gockerman JP. Rituximab in lymphocyte predominance Hodgkin's disease: a case series. Blood. 2003 Jun 1;101(11):4285-9. [http://bloodjournal.hematologylibrary.org/content/101/11/4285.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12586628 PubMed] | # Ibom VK, Prosnitz RG, Gong JZ, Moore JO, DeCastro CM, Prosnitz LR, Rizzieri DA, Gockerman JP. Rituximab in lymphocyte predominance Hodgkin's disease: a case series. Blood. 2003 Jun 1;101(11):4285-9. [http://bloodjournal.hematologylibrary.org/content/101/11/4285.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12586628 PubMed] | ||
# Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008 Jan 1;111(1):109-11. [http://bloodjournal.hematologylibrary.org/content/111/1/109.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17938252 PubMed] | # Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008 Jan 1;111(1):109-11. [http://bloodjournal.hematologylibrary.org/content/111/1/109.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17938252 PubMed] |
Revision as of 21:10, 5 July 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Untreated
ABVD
ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine
Regimen
- Doxorubicin (Adriamycin) 25 mg/m2 IV once on days 1 & 15
- Bleomycin (Blenoxane) 10 units/m2 IV once on days 1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose)
- Vinblastine (Velban) 6 mg/m2 IV once on days 1 & 15
- Dacarbazine (DTIC) 375 mg/m2 IV once on days 1 & 15
- +/- Rituximab (Rituxan); schedule & number of cycles is not well-established. One potential option is 375 mg/m2 IV weekly x 4 weeks on cycle 1 (see single agent rituximab). Use in subsequent cycles is not well-documented.
28-day cycles x 2 to 6 cycles based on stage, response, and whether radiation therapy is used.
References
- Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011 Oct 27;118(17):4585-90. link to original article PubMed
CHOP
CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Regimen
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once daily on days 1 to 5
21-day cycles x 6 to 8 cycles (number of cycles for CHOP in LPHL is not well-established)
References
- Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. link to original article contains protocol--this was for diffuse large B-cell lymphomas; no primary reference available for use of CHOP in LPHL PubMed
R-CHOP
R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Regimen
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once daily on days 1 to 5
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
21-day cycles x 6 to 8 cycles (number of cycles for R-CHOP in LPHL is not well-established)
References
CVP
CVP: Cyclophosphamide, Vincristine, Prednisone
Regimen
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1
- Prednisone (Sterapred) 40 mg/m2 PO once daily on days 1 to 5
21-day cycles x up to 8 cycles (number of cycles for CVP in LPHL is not well-established)
References
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105(4):1417-23. link to original article contains protocol--this was for follicular lymphoma; no primary reference available for use of CVP in LPHL PubMed
R-CVP
R-CVP: Rituximab, Cyclophosphamide, Vincristine, Prednisone
Regimen
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2mg per cycle) IV once on day 1
- Prednisone (Sterapred) 40 mg/m2 PO once daily on days 1 to 5
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
21-day cycles x up to 8 cycles (number of cycles for R-CVP in LPHL is not well-established)
References
EPOCH
EPOCH: Etoposide, Prednisone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin
Regimen #1, Wilson, et al. 1993 - original EPOCH protocol
- Etoposide (Vepesid) 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4
- Prednisone (Sterapred) 60 mg/m2/day PO on days 1 to 5 (regimen originally was days 1 to 6, but now is just days 1 to 5)
- Vincristine (Oncovin) 0.4 mg/m2/day (1.6 mg/m2 total) (sometimes capped at maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4
- Doxorubicin (Adriamycin) 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 15 minutes on day 5 (regimen originally was day 6, but now is day 5)
- PCP prophylaxis (choose one)
- Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO BID 3 days per week
- Atovaquone (Mepron) 1500 mg PO daily
- Pentamidine (Nebupent) 300 mg nebulized Q28days
- Filgrastim (Neupogen) 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir
21-day cycles x 6 to 8 cycles
Regimen #2, Wilson, et al. 2002 - dose-adjusted EPOCH
- Etoposide (Vepesid) 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4
- Prednisone (Sterapred) 60 mg/m2 PO BID on days 1 to 5
- Vincristine (Oncovin) 0.4 mg/m2/day (1.6 mg/m2 total) (not capped in the paper, but sometimes capped at a maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4
- Doxorubicin (Adriamycin) 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 15 minutes on day 5
- PCP prophylaxis (choose one)
- Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO BID 3 days per week
- Atovaquone (Mepron) 1500 mg PO daily
- Pentamidine (Nebupent) 300 mg nebulized Q28days
- Filgrastim (Neupogen) 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir
21-day cycles x 6 to 8 cycles
Dose-adjustments for EPOCH protocol:
- Start cycle 1 as described above
- Obtain twice per week CBCs for nadir measurements
- If nadir ANC >500, increase etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
- If nadir ANC <500 on 1 or 2 measurements, use same doses as last cycle
- If nadir ANC <500 on at least 3 measurements, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
- And/or if nadir platelet count <25 on at least 1 measurement, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
- Dose adjustments below the cycle 1 starting dose only applies to cyclophosphamide. The lowest etoposide and doxorubicin would be dosed at is the original cycle 1 dose.
- Can start new cycle Q21days if ANC >1,000 and platelets >100. If counts are below those levels, check daily CBC and continue growth factor support until counts are adequate and next cycle can start.
Historic dose adjustments for hematologic toxicity:
These adjustments were in the original paper for standard EPOCH, which are much less relevant due to growth factor support.
If ANC on day 1 is:
- >1,500, full dose cyclophosphamide
- 1,000-1,500, reduce cyclophosphamide by 187 mg/m2 (equal to 25% dose reduction)
- <1,000, hold EPOCH
- If ANC nadir is <500, reduce cyclophosphamide an additional 187 mg/m2
- If ANC nadir is >500 and patient had previously been dose-reduced, increase cyclophosphamide dose by 187 mg/m2
References
- Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993 Aug;11(8):1573-82 link to original article contains protocol PubMed
- Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685-93. link to original article contains protocol PubMed content property of HemOnc.org
- Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008 Jun 1;26(16):2717-24. link to original article PubMed
R-EPOCH
R-EPOCH: Rituximab, Etoposide, Prednisone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin
Regimen #1, Wilson, et al. 1993 - original EPOCH protocol (which did not include rituximab)
- Rituximab (Rituxan) 375 mg/m2 IV once per cycle (usually given as outpatient due to reimbursement issues)
- Etoposide (Vepesid) 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4
- Prednisone (Sterapred) 60 mg/m2/day PO on days 1 to 5 (regimen originally was days 1 to 6, but now is just days 1 to 5)
- Vincristine (Oncovin) 0.4 mg/m2/day (1.6 mg/m2 total) (sometimes capped at maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4
- Doxorubicin (Adriamycin) 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 15 minutes on day 5 (regimen originally was day 6, but now is day 5)
- PCP prophylaxis (choose one)
- Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO BID 3 days per week
- Atovaquone (Mepron) 1500 mg PO daily
- Pentamidine (Nebupent) 300 mg nebulized Q28days
- Filgrastim (Neupogen) 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir
21-day cycles x 6 to 8 cycles
Regimen #2, Wilson, et al. 2002 - dose-adjusted EPOCH
- Rituximab (Rituxan) 375 mg/m2 IV once per cycle (usually given as outpatient due to reimbursement issues)
- Etoposide (Vepesid) 50 mg/m2/day (200 mg/m2 total) IV continuous infusion on days 1 to 4
- Prednisone (Sterapred) 60 mg/m2 PO BID on days 1 to 5
- Vincristine (Oncovin) 0.4 mg/m2/day (1.6 mg/m2 total) (not capped in the paper, but sometimes capped at a maximum total dose of 2mg per cycle) IV continuous infusion on days 1 to 4
- Doxorubicin (Adriamycin) 10 mg/m2/day (40 mg/m2 total) IV continuous infusion on days 1 to 4
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 15 minutes on day 5
- PCP prophylaxis (choose one)
- Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO BID 3 days per week
- Atovaquone (Mepron) 1500 mg PO daily
- Pentamidine (Nebupent) 300 mg nebulized Q28days
- Filgrastim (Neupogen) 5 mcg/kg SQ daily start day 6 and continue until ANC >5,000/uL past nadir
21-day cycles x 6 to 8 cycles
Dose-adjusted R-EPOCH protocol
- Start cycle 1 as described above
- Obtain twice per week CBCs for nadir measurements
- If nadir ANC >500, increase etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
- If nadir ANC <500 on 1 or 2 measurements, use same doses as last cycle
- If nadir ANC <500 on at least 3 measurements, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
- And/or if nadir platelet count <25 on at least 1 measurement, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
- Dose adjustments below the cycle 1 starting dose only applies to cyclophosphamide. The lowest etoposide and doxorubicin would be dosed at is the original cycle 1 dose.
- Can start new cycle Q21days if ANC >1,000 and platelets >100. If counts are below those levels, check daily CBC and continue growth factor support until counts are adequate and next cycle can start.
Historic dose adjustments for hematologic toxicity
These adjustments were in the original paper for standard EPOCH, which are much less relevant due to growth factor support.
If ANC on day 1 is:
- >1,500, full dose cyclophosphamide
- 1,000-1,500, reduce cyclophosphamide by 187 mg/m2 (equal to 25% dose reduction)
- <1,000, hold EPOCH
- If ANC nadir is <500, reduce cyclophosphamide an additional 187 mg/m2
- If ANC nadir is >500 and patient had previously been dose-reduced, increase cyclophosphamide dose by 187 mg/m2
References
Single agent Rituximab (Rituxan)
Regimen
- Rituximab (Rituxan) 375 mg/m2 IV weekly x 4 weeks
One course of 4 week therapy
Supportive medications
- Acetaminophen 650 mg PO 30 minutes prior to each dose of rituximab
- Diphenhydramine (Benadryl) 25 mg PO 30 minutes prior to each dose of rituximab
References
- Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Jun 1;101(11):4285-9. link to original article contains protocol PubMed
- Ibom VK, Prosnitz RG, Gong JZ, Moore JO, DeCastro CM, Prosnitz LR, Rizzieri DA, Gockerman JP. Rituximab in lymphocyte predominance Hodgkin's disease: a case series. Blood. 2003 Jun 1;101(11):4285-9. link to original article contains protocol PubMed
- Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008 Jan 1;111(1):109-11. link to original article contains protocol PubMed